BR9903382A - Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos - Google Patents

Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos

Info

Publication number
BR9903382A
BR9903382A BR9903382-8A BR9903382A BR9903382A BR 9903382 A BR9903382 A BR 9903382A BR 9903382 A BR9903382 A BR 9903382A BR 9903382 A BR9903382 A BR 9903382A
Authority
BR
Brazil
Prior art keywords
poly
acrylic
carbidopa
methacrylic acid
dopa
Prior art date
Application number
BR9903382-8A
Other languages
English (en)
Inventor
Fabio Moyses Lins Dantas
David Tabak
Cristina Tristao De Andrade
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to BR9903382-8A priority Critical patent/BR9903382A/pt
Priority to GB0111066A priority patent/GB2384426A/en
Priority to PCT/BR2000/000086 priority patent/WO2001010378A2/en
Priority to CA002346291A priority patent/CA2346291A1/en
Priority to AU61426/00A priority patent/AU6142600A/en
Priority to EP00947704A priority patent/EP1117370A1/en
Priority to DE10082749T priority patent/DE10082749T1/de
Publication of BR9903382A publication Critical patent/BR9903382A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "COPOLìMEROS DE áCIDO ACRìLICO OU METACRìLICO/L-DOPA, DE áCIDO ACRìLICO OU METACRìLICO/L-<244>-METILDOPA OU DE áCIDO ACRìLICO OU METACRìLICO/L-CARBIDOPA, PROCESSO DE SUA OBTENçãO E COMPOSIçõES MEDICAMENTOSAS CONTENDO OS MESMOS" A presente invenção tem relação com sistemas de distribuição de drogas do tipo vetorizado, propiciando a liberação controlada de L-dopa, carbidopa, L-<244>-metildopa e/ou suas combinações, com o objetivo de eliminar ou pelo menos reduzir os efeitos colaterais deletérios das mesmas. Os copolímeros biologicamente ativos tendo características do tipo sítio dirigido para tecido mucoso do sistema digestivo compreendem L-dopa, carbidopa ou L-<244>-metildopa quimicamente combinados com poli (ácido acrílico) ou poli (ácido metacrílico) biologicamente aceitável. Os copolímeros são obtidos através de um processo compreendendo as etapas de: (a) reação da L-dopa, carbidopa ou L-<244>-metildopa com um agente de cloração; (b) reação do produto da etapa (a) com poli (ácido acrílico) ou poli (ácido metacrílico) na presença de um catalisador apropriado; (c) lavagem do copolímero obtido na etapa (b) com um solvente orgânico apropriado e processamento de sua secagem até o alcance de peso constante. Os medicamentos anti-hipertensivos de liberação controlada da presente invenção compreendem pelo menos um copolímero biologicamente ativo selecionado do grupo consistindo de poli (ácido acrílico/L-<244>-metildopa), poli (ácido acrílico/carbidopa), poli (ácido metacrílico/carbidopa), ou suas combinações, e um veículo farmaceuticamente aceitável. Os medicamentos de liberação controlada da presente invenção também compreendem pelo menos um copolímero biologicamente ativo selecionado do grupo consistindo de poli (ácido acrílico/L-dopa), poli (ácido metacrílico/L-dopa), poli (ácido acrílico/carbidopa), poli (ácido metacrílico/carbidopa) ou suas combinações e um veículo farmaceuticamente aceitável os quais podem ser usados no tratamento da síndrome de Parkinson.
BR9903382-8A 1999-08-04 1999-08-04 Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos BR9903382A (pt)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR9903382-8A BR9903382A (pt) 1999-08-04 1999-08-04 Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos
GB0111066A GB2384426A (en) 1999-08-04 2000-08-02 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-α-Methyl dopa, acrylic or methacrylic
PCT/BR2000/000086 WO2001010378A2 (en) 1999-08-04 2000-08-02 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations
CA002346291A CA2346291A1 (en) 1999-08-04 2000-08-02 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-.alpha.-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations
AU61426/00A AU6142600A (en) 1999-08-04 2000-08-02 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-alpha-methyl dopa, acrylic or methacrylic acid/carbidopaand their combinations
EP00947704A EP1117370A1 (en) 1999-08-04 2000-08-02 CONTROLLED RELEASE FROM COPOLYMERS OF ACRYLIC OR METHACRYLIC ACID/L-DOPA, ACRYLIC OR METHACRYLIC ACID/L-$g(a)-METHYL DOPA, ACRYLIC OR METHACRYLIC ACID/CARBIDOPA AND THEIR COMBINATIONS
DE10082749T DE10082749T1 (de) 1999-08-04 2000-08-02 Kontrollierte Freisetzung aus Copolymeren von Acryl- oder Methacrylsäure/L-Dopa, Acryl- oder Methacrylsäure/L-a-Methyldopa, Acryl- oder Methacrylsäure/Carbidopa und deren Kombinationen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR9903382-8A BR9903382A (pt) 1999-08-04 1999-08-04 Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos

Publications (1)

Publication Number Publication Date
BR9903382A true BR9903382A (pt) 2001-03-20

Family

ID=4073069

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9903382-8A BR9903382A (pt) 1999-08-04 1999-08-04 Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-<244> metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos

Country Status (7)

Country Link
EP (1) EP1117370A1 (pt)
AU (1) AU6142600A (pt)
BR (1) BR9903382A (pt)
CA (1) CA2346291A1 (pt)
DE (1) DE10082749T1 (pt)
GB (1) GB2384426A (pt)
WO (1) WO2001010378A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056708A2 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
JP2008516893A (ja) * 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2007002318A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Bioadhesive polymers
EP2324810B1 (de) 2009-11-19 2014-10-29 Ivoclar Vivadent AG Gefüllter Dentalwerkstoff auf der Basis von polymerisationsfähigen Dihydroxyphenylalanin-Derivaten
CN117919217A (zh) * 2022-10-14 2024-04-26 浙江华海药业股份有限公司 一种用于治疗帕金森病的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
ATE203029T1 (de) * 1990-10-24 2001-07-15 Masayuki Kuzuya Organische polymerverbindung und ihre herstellung

Also Published As

Publication number Publication date
GB0111066D0 (en) 2001-06-27
GB2384426A (en) 2003-07-30
WO2001010378A3 (en) 2001-08-30
WO2001010378A2 (en) 2001-02-15
DE10082749T1 (de) 2001-11-22
EP1117370A1 (en) 2001-07-25
CA2346291A1 (en) 2001-02-15
AU6142600A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
Kurakula et al. Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition
Risbud et al. pH-sensitive freeze-dried chitosan–polyvinyl pyrrolidone hydrogels as controlled release system for antibiotic delivery
Foss et al. Development of acrylic-based copolymers for oral insulin delivery
Khan et al. Gelatin/carboxymethyl cellulose based stimuli-responsive hydrogels for controlled delivery of 5-fluorouracil, development, in vitro characterization, in vivo safety and bioavailability evaluation
Dodane et al. Pharmaceutical applications of chitosan
Avadi et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method
Sreenivas et al. Thiolated chitosans: novel polymers for mucoadhesive drug delivery–a review
KR20000069044A (ko) 경피 전달계
BRPI0414017A (pt) pró-fármacos poliméricos de múltiplos braços
BR9916721A (pt) Polìmero anfolìtico hidrofìlico, copolìmeroanfolìtico hidrofìlico, método para preparar umcopolìmero polimérico anfolìtico hidrofìlico,formulação aquosa espessada, xampu eformulação de condicionamento, amaciante têxtil,composição para fornecimento oral de ummedicamento ou substância ativa, método paraaperfeiçoar o transporte de um medicamentofornecido oralmente do sistema digestivo parauma corrente sanguìnea, uso do polìmero, e,método para remover fosfato de um paciente
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
Oprea et al. Synthesis and characterization of some cellulose/chondroitin sulphate hydrogels and their evaluation as carriers for drug delivery
JPH05508631A (ja) 結腸用薬物送達システム
BR9901782A (pt) Forma para dosagem de nefazodona.
JPH09100235A (ja) 架橋ポリビニルピロリドン−ヨウ素複合物及びその製造方法
KR101066763B1 (ko) 온도 반응성 전달계
EP1061904A1 (de) Nanopartikel, verfahren zu ihrer herstellung und ihre verwendung
ES2325626T3 (es) Matrices de hidrogel anionico con liberacion modificada dependiente del ph como vehiculos farmacologicos.
BR9903382A (pt) Copolìmeros de ácido acrìlico ou metacrìlico/l-dopa, de ácido acrìlico ou metacrìlico/l-&lt;244&gt; metildopa ou de ácido acrìlico ou metacrìlico/l-carbidopa, processo de sua obtenção e composições medicamentosas contendo os mesmos
Nho et al. Preparation, properties and biological application of pH-sensitive poly (ethylene oxide)(PEO) hydrogels grafted with acrylic acid (AAc) using gamma-ray irradiation
Kumarasamy et al. Biopolysaccharide-based hydrogel materials for drug delivery
Kumar et al. Interpenetrating polymeric network hydrogel for stomach-specific drug delivery of clarithromycin: Preparation and evaluation
Dhakar pH-sensitive interpenetrating hydrogel for eradication of Helicobacter pylori
Patsialas et al. Encapsulation of the peptide Ac–Glu–Thr–Lys–Thr–Tyr–Phe–Trp–Lys–NH2 into polyvinyl alcohol biodegradable formulations—Effect of calcium alginate

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A , 6A E 7A ANUIDADES.